Context

Although Systolic Hypertension in Europe1 and Heart Outcomes Prevention Evaluation2 studies suggested nightly dosing of antihypertensive medications might lead to better cardiovascular outcomes, the Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular trial (ABPM),3 or Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares (MAPEC), was the first study to include a comparison group randomised to morning only therapy. MAPEC showed improved blood pressure (BP) control, increased prevalence of normal sleep time blood pressure decline (ie, dipping) and reduced cardiovascular morbidity and mortality with nighttime chronotherapy. Since people with diabetes are prone to nocturnal …